Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Non-cash Items (2021 - 2025)

ARS Pharmaceuticals (SPRY) has disclosed Non-cash Items for 5 consecutive years, with $42.4 million as the latest value for Q4 2025.

  • Quarterly Non-cash Items rose 3.16% to $42.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $42.4 million through Dec 2025, up 3.16% year-over-year, with the annual reading at $42.4 million for FY2025, 3.16% up from the prior year.
  • Non-cash Items hit $42.4 million in Q4 2025 for ARS Pharmaceuticals, down from $48.3 million in the prior quarter.
  • In the past five years, Non-cash Items ranged from a high of $39.4 billion in Q1 2023 to a low of $4.6 million in Q4 2022.
  • Historically, Non-cash Items has averaged $3.5 billion across 5 years, with a median of $48.3 million in 2025.
  • Biggest five-year swings in Non-cash Items: tumbled 99.96% in 2022 and later skyrocketed 79151.9% in 2023.
  • Year by year, Non-cash Items stood at $11.4 billion in 2021, then crashed by 99.96% to $4.6 million in 2022, then surged by 445.17% to $25.1 million in 2023, then surged by 63.89% to $41.1 million in 2024, then rose by 3.16% to $42.4 million in 2025.
  • Business Quant data shows Non-cash Items for SPRY at $42.4 million in Q4 2025, $48.3 million in Q3 2025, and $53.9 million in Q2 2025.